Green Cross Lab Cell Corporation Total Liabilities
Green Cross Lab Cell Corporation total liabilities. Based on the latest financial reports, Green Cross Lab Cell Corporation (144510) has total liabilities worth ₩145.87 Billion KRW (≈ $98.85 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of Green Cross Lab Cell Corporation to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Green Cross Lab Cell Corporation (2015–2025)
Total liabilities of Green Cross Lab Cell Corporation from 2015 to 2025. This chart illustrates how Green Cross Lab Cell Corporation's total liabilities have evolved over time, based on quarterly financial data. Explore Green Cross Lab Cell Corporation long-term investment intensity to see how much of total assets are deployed in long-term investments.
Green Cross Lab Cell Corporation Competitors by Total Liabilities
The table below lists competitors of Green Cross Lab Cell Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
SaltX Technology Holding AB
ST:SALT-B
|
Sweden | Skr33.22 Million |
|
Asia Pacific Satellite Inc
KQ:211270
|
Korea | ₩22.41 Billion |
|
The Hi-Tech Gears Limited
NSE:HITECHGEAR
|
India | Rs3.17 Billion |
|
Odlewnie Polskie SA
WAR:ODL
|
Poland | zł62.72 Million |
|
Samyang Packaging
KO:272550
|
Korea | ₩263.20 Billion |
|
Ulusoy Un Sanayi ve Ticaret AS
IS:ULUUN
|
Turkey | TL31.13 Billion |
|
LINMON MEDIA LTD -000025
F:8MN
|
Germany | €832.79 Million |
|
Hiap Teck Venture Bhd
KLSE:5072
|
Malaysia | RM605.18 Million |
Liability Composition Analysis (2015–2025)
This chart breaks down Green Cross Lab Cell Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Green Cross Lab Cell Corporation total assets.
Liquidity & Leverage Metrics
Green Cross Lab Cell Corporation Total Liabilities Ratios Explained
Green Cross Lab Cell Corporation total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.52 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.79 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.44 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Green Cross Lab Cell Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Green Cross Lab Cell Corporation (2015–2025)
The table below shows the annual total liabilities of Green Cross Lab Cell Corporation from 2015 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | ₩113.31 Billion ≈ $76.79 Million |
-6.01% |
| 2024-12-31 | ₩120.56 Billion ≈ $81.70 Million |
-2.53% |
| 2023-12-31 | ₩123.69 Billion ≈ $83.82 Million |
-10.42% |
| 2022-12-31 | ₩138.07 Billion ≈ $93.57 Million |
+2.60% |
| 2021-12-31 | ₩134.57 Billion ≈ $91.20 Million |
+360.97% |
| 2020-12-31 | ₩29.19 Billion ≈ $19.78 Million |
+21.56% |
| 2019-12-31 | ₩24.02 Billion ≈ $16.27 Million |
+151.56% |
| 2018-12-31 | ₩9.55 Billion ≈ $6.47 Million |
+35.76% |
| 2017-12-31 | ₩7.03 Billion ≈ $4.77 Million |
+9.59% |
| 2016-12-31 | ₩6.42 Billion ≈ $4.35 Million |
-18.81% |
| 2015-12-31 | ₩7.90 Billion ≈ $5.36 Million |
-- |
About Green Cross Lab Cell Corporation
GC Cell Corporation develops cell therapy products. It also provides cell banking, sample inspection, clinical trial, and bio logistics services. Its main product is Immuncell-LC. GC Cell Corporation has strategic agreement with Lukas Biomedical Co., Ltd. to develop Cell therapy. The company was formerly known as Green Cross Lab Cell Corporation and changed its name to GC Cell Corporation in Nove… Read more